Valuation, from the filing
| Public float | $4.25B | Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-30 |
|---|---|---|
| Float per share | $13.48 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
| Float / revenue | 13.3× | A lower bound on the multiple, because affiliate holdings are excluded. |
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.
How this compares in its industry
Percentile among the Finance Services filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
| Measure | Reported | Percentile | |
|---|---|---|---|
| CapEx / revenue | 228.5% | 92th | |
| Revenue YoY growth | -37.5% | 11th | |
| Gross margin | 11.9% | 23th | |
| FCF margin | -141.3% | 27th | |
| SBC / revenue | 30.8% | 66th | |
| Operating margin | -77.0% | 62th | |
| Current ratio | 1.15x | 41th | |
| Net margin | -90.5% | 55th |
Core Scientific, Inc./tx (CORZ) reported revenue of $440.31M and net income of -$1.43B for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Core Scientific, Inc./tx’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Finance Services.
Banks, brokers and insurers present a top line that is not comparable with an operating company’s revenue: it is reported net of interest expense, or as premiums earned, depending on the filer. The figures are the filer’s own and are traceable to the filing; the comparison across classes is what does not hold.
Income
| Metric | 2026-06-30 |
|---|---|
| Revenue | $440.31M |
| Cost of revenue | $315.50M |
| Gross profit | $124.81M |
| Operating income | -$561.16M |
| Net income | -$1.43B |
| Research & development | Unavailable |
| Weighted-average diluted shares | Unavailable |
| Pretax income | -$1.43B |
| Income tax expense | $2.73M |
| Diluted EPS | Unavailable |
| Selling, general & administrative | $151.96M |
| General & administrative | Unavailable |
| Selling & marketing | Unavailable |
Balance
| Metric | 2026-06-30 |
|---|---|
| Cash & equivalents | $1.77B |
| Total assets | $5.26B |
| Current assets | $2.44B |
| Total liabilities | $7.68B |
| Current liabilities | $2.74B |
| Total equity incl. NCI | -$2.42B |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | Unavailable |
| Accounts receivable | Unavailable |
| Goodwill | Unavailable |
| Long-term debt | $4.30B |
| Accounts payable | $112.37M |
Cash flow
| Metric | 2026-06-30 |
|---|---|
| Operating cash flow | $520.24M |
| Capital expenditures | $1.48B |
| Investing cash flow | -$1.72B |
| Financing cash flow | $3.16B |
| Net change in cash | $1.97B |
| Stock-based compensation | $93.88M |
| Common dividends paid | Unavailable |
| Common share repurchases | Unavailable |
| Depreciation & amortization | $62.57M |
Derived
| Metric | 2026-06-30 |
|---|---|
| Free cash flow | -$957.74M |
| Gross margin | 28.3% |
| Operating margin | -127.4% |
| FCF margin | -217.5% |
| SBC / revenue | 21.3% |
| Current ratio | 0.89x |
| Revenue YoY growth | 26.4% |
| Net margin | -324.9% |
| R&D / revenue | Unavailable |
| CapEx / revenue | 335.7% |
| Long-term debt / equity | Unavailable |
| Effective tax rate | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CORZ in the interactive workspace to inspect any figure back to its filing.
Source filings
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.